Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab +/- Relatlimab or Ipilimumab in Advanced Basal Cell Carcinoma
NCT03521830Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2018
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in basal cell carcinoma (BCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Nov 2018; status: recruiting.
02
Drugs
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03521830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03521830.